Experimental CAR T-Cell therapy targets two proteins to fight tough lymphoma
NCT ID NCT06295549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new cell therapy called LUCAR-G39P in 11 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to attack two targets (CD19 and CD20) on cancer cells. The main goals were to check safety, side effects, and find the right dose. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LUCAR-G39P cells (a type of CAR T-cell therapy that targets two proteins, CD19 and CD20, on cancer cells)
- What this could lead to
- If this therapy works, it could offer a new treatment option for patients with hard-to-treat B-cell lymphoma that has come back after other treatments.
- What could go wrong
- This is a very early phase 1 trial with only 11 patients, and it was terminated early. The therapy may cause serious side effects, and it is unknown if it will be effective or safe for broader use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
11 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent. 2. Aged 18-75 years (inclusive). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20. 5. At least one evaluable tumor lesion according to Lugano 2014 criteria. Response to prior therapy is consistent with one of the following: 1. Primary refractory. 2. Relapsed or refractory after 2 or more lines of therapy. 3. For LBCL, 3B FL. t-iNHL: * Relapse within 12 months after first-line chemoimmunotherapy to achieve CR; * Progression or relapse within 12 months after autologous hematopoietic stem cell transplantation; 7\. Life expectancy≥ 3 months 8. Clinical laboratory values meet screening visit criteria Exclusion Criteria: Subject eligible for this study must not meet any of the following criteria: 1. Prior antitumor therapy with insufficient washout period ; 2. Patients who received autologous CAR-T cell therapy (except CD19-targeted) or autologous gene therapy; 3. Patients who received allogeneic hematopoietic stem cell transplantation or allogeneic therapy; 5\. Patients who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), or human immunodeficiency virus antibody (HIV- Ab). 6\. Known life-threatening allergies, hypersensitivity, or intolerance to LUCAR-G39P CAR-T cell or its excipients, including DMSO. 7\. Pregnant or lactating women; \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed and refractory B-cell non-Hodgkin lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Beijing Gobroad Hosptial
Beijing, 102206, China
-
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.